Enanta’s Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is one of the best hot stocks to invest in. On September 29, Enanta Pharmaceuticals reported positive topline results from its Phase 2b study/RSVHR of zelicapavir. Zelicapavir is a novel N-protein inhibitor with Fast Track designation from the FDA, being developed as a once-daily oral treatment for acute Respiratory Syncytial Virus/RSV infection in high-risk adult outpatients.

The study was a randomized, double-blind, placebo-controlled, proof-of-concept trial designed to inform the design of a Phase 3 study, including endpoints and populations, by assessing the antiviral treatment effect on symptoms using the RiiQ (Respiratory Infection Intensity and Impact Questionnaire) patient-reported outcome tool.

Enanta's Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults

Zelicapavir is a lead N-protein inhibitor that targets the virus’s replication machinery, showing a high barrier to resistance in vitro and maintaining antiviral potency across all clinical isolates tested. It is differentiated from RSV fusion inhibitors. The drug has shown a consistent safety profile in 600+ people exposed to date. RSV is a common respiratory virus that poses an increased risk of severe illness, hospitalization, and death for older adults and those with underlying conditions like COPD, CHF, or asthma.

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is a biotechnology company that discovers and develops small-molecule drugs for the treatment of viral infections and liver diseases.

While we acknowledge the potential of ENTA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ENTA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.